Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 18.4% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management solutions, including insulin pumps. The overall market sentiment towards TNDM has been positive recently, with a focus on long-term growth strategies and equity compensation activities among key personnel.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 18.4% on May 29, 2026 14:20

• Maintaining a Neutral rating but lowering the price target could have initially caused some uncertainty, but the undervaluation by 43.8% may have sparked investor interest.
• The approval of an expanded long-term incentive plan and progress on new insulin pump launches indicate the company's commitment to long-term growth, potentially boosting investor confidence.
• The equity compensation activities of key figures like Chair Emeritus Dick Allen and Director Sandra Beaver, receiving RSUs and aligning their interests with shareholders, could have contributed to a positive outlook for the company.
• Overall, the combination of strategic growth initiatives, undervaluation, and alignment of interests through equity compensation may have driven the strong bullish movement in TNDM's stock today.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

TNDM Maintained by Citigroup -- Price Target Lowered to $17

Citigroup analyst Joanne Wuensch maintained a Neutral rating on Tandem Diabetes Care (TNDM) but lowered the price target from $22.00 to $17.00, reflecting a cautious outlook due to changing market conditions and competitive pressures. GuruFocus indicates TNDM is currently undervalued by 43.8% based on its GF Value™, yet the stock carries a "Possible Value Trap" label and insider selling has occurred. Investors are advised to proceed with caution despite the undervaluation, considering the mixed signals.

https://www.gurufocus.com/news/8889523/tndm-maintained-by-citigroup-price-target-lowered-to-17

Does Tandem Diabetes Care’s (TNDM) Expanded Incentive Plan Clarify Its Long‑Term Growth Priorities?

Tandem Diabetes Care (TNDM) recently gained shareholder approval for an expanded long-term incentive plan, re-elected directors, and ratified its auditor, alongside announcing progress on new insulin pump launches. This move aims to align management and shareholder goals for long-term growth, with the expanded incentive plan crucial for retaining the team vital for product execution. While the company projects significant revenue and earnings growth by 2029, investors should be aware of intensifying competition and potential pressures on margins.

https://www.sahmcapital.com/news/content/does-tandem-diabetes-cares-tndm-expanded-incentive-plan-clarify-its-longterm-growth-priorities-2026-05-22

Tandem Diabetes Care (TNDM) chair emeritus reports new RSU grant and vesting

Tandem Diabetes Care's Chair Emeritus, Dick Allen, reported recent equity compensation activities. He received 10,220 Restricted Stock Units (RSUs) on May 20, 2026, which will vest in one year. Additionally, 8,759 previously granted RSUs vested and converted into common shares, increasing his direct holdings to 28,146 shares, with an additional 22,757 shares held indirectly through a family trust.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-371d1372dd72.html

Tandem Diabetes (TNDM) director reports 10,220 RSU grant and 8,759-share vesting

Peyton R. Howell, a director at Tandem Diabetes Care (TNDM), reported significant equity award activity. This included the vesting and exercise of 8,759 restricted stock units into common shares on May 21, 2026, increasing her direct holdings to 29,836 shares. Additionally, Howell received a new grant of 10,220 restricted stock units on May 20, 2026, which are set to vest one year from the grant date under the company’s 2023 Long-Term Incentive Plan.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-6d70f7b8d8f7.html

Tandem Diabetes Care (TNDM) director receives 5,110 restricted stock units grant

Tandem Diabetes Care (TNDM) director Sandra Beaver was granted 5,110 restricted stock units (RSUs) on May 20, 2026, as reported in a Form 4 SEC filing. These RSUs represent a contingent right to receive either common stock or cash and will fully vest on the one-year anniversary of the grant date, in accordance with the company's 2023 Long-Term Incentive Plan. This equity award serves to align the director's interests with those of shareholders.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-a7842aaf50c1.html

Trending Today

Prime Medicine ($PRME) Stock Forecast: Up 6.5% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 13.1% Today

Ford Motor Company ($F) Stock Forecast: Up 5.3% Today

Broadcom Inc. ($AVGO) Stock Forecast: Up 5.0% Today

Microsoft Corporation ($MSFT) Stock Forecast: Up 5.3% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Down 2.8% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 9.4% Today

Clorox Company (The) ($CLX) Stock Forecast: Down 5.6% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 8.5% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.3% Today

Tandem Diabetes Care, Inc. Price History

29.04.2026 - TNDM Stock was up 18.4%

• Maintaining a Neutral rating but lowering the price target could have initially caused some uncertainty, but the undervaluation by 43.8% may have sparked investor interest.
• The approval of an expanded long-term incentive plan and progress on new insulin pump launches indicate the company's commitment to long-term growth, potentially boosting investor confidence.
• The equity compensation activities of key figures like Chair Emeritus Dick Allen and Director Sandra Beaver, receiving RSUs and aligning their interests with shareholders, could have contributed to a positive outlook for the company.
• Overall, the combination of strategic growth initiatives, undervaluation, and alignment of interests through equity compensation may have driven the strong bullish movement in TNDM's stock today.

13.04.2026 - TNDM Stock was down 5.5%

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

01.04.2026 - TNDM Stock was up 7.7%

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

15.04.2026 - TNDM Stock was down 10.5%

• Tandem Diabetes Care (TNDM) posted a narrower loss, surpassed revenue expectations, and notably expanded its gross margin. Interestingly, the stock saw a significant 23.6% decline post-earnings, sparking speculation on potential factors:
• Market sentiment may have soured over doubts about the company's sustainability of growth or concerns regarding future sales performance, despite confirming its annual sales outlook.
• The 'Hold' rating from Benchmark upon initiating coverage, suggesting a balanced valuation and potential volatility, could have contributed to investor wariness, leading to downward stock pressure.
• Despite technical signals indicating a possible trend shift, a recent 26.5% decrease in TNDM's share price across four weeks might have influenced investor sentiment, prompting profit-taking and sell-offs.
• Ultimately, a blend of market sentiment, analyst evaluations, and technical indicators likely converged to shape a pessimistic short-term outlook for Tandem Diabetes Care (TNDM), contrasting with positive financial results and growth potential in the long run.

27.04.2026 - TNDM Stock was down 5.0%

• Shareholders' approval of an expanded long-term incentive plan and recent equity compensation activities involving key individuals at Tandem Diabetes Care could have raised concerns among investors regarding the company's long-term growth outlook and talent retention.
• The company's issuance of stock-based compensation and the granting of restricted stock units (RSUs) to directors may have sparked uncertainties about TNDM's financial stability and strategic path, leading to a lack of confidence in its future performance.
• Despite advancements in new insulin pump releases and optimistic revenue and earnings growth forecasts by 2029, the intensifying competition and possible margin pressures mentioned in recent updates might have contributed to TNDM's bearish market activity.
• The emphasis on aligning management and shareholder objectives for prolonged growth, while crucial, may have also highlighted existing hurdles and uncertainties within the company, further influencing investor sentiment and prompting the downward movement in TNDM's stock price.

20.04.2026 - TNDM Stock was up 5.1%

• Tandem Diabetes Care (TNDM) experienced a bullish market movement today, likely driven by positive sentiment and confidence in the company's leadership and growth prospects.
• The routine equity compensation activities reported by TNDM's legal chief, CTO, and EVP may have instilled trust and stability among investors, showcasing commitment and alignment of interests with shareholders.
• The focus on the "Silver Economy" and the healthcare sector's growth opportunities, including TNDM's innovative initiatives, could have further boosted investor optimism and contributed to the stock's upward momentum.
• Despite a price target cut by B of A Securities, the overall positive industry outlook and company-specific developments seem to have outweighed this factor, leading to the bullish movement in TNDM's stock price.

08.04.2026 - TNDM Stock was down 9.7%

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

04.04.2026 - TNDM Stock was down 5.0%

• A notable passive institutional investment by Vanguard Capital Management in Tandem Diabetes Care may have indicated lack of confidence in the company's future, influencing the bearish trend.
• Despite TD Cowen increasing TNDM's price target and maintaining a Buy rating, the market's negative reaction to the company's announcement of upcoming investor conference details might have led to market pessimism.
• Investors possibly engaged in profit-taking due to the anticipation of Tandem Diabetes Care's presentations at upcoming investor conferences, which could have driven down the stock price.
• Shifting market sentiment towards medical stocks priced below $30 could have impacted Tandem Diabetes Care's stock performance, notwithstanding positive forecasts for future revenue growth.

06.04.2026 - TNDM Stock was down 5.2%

• The FDA clearance for Tandem's Control-IQ+ technology for pregnant individuals with type 1 diabetes could have raised concerns among investors about potential regulatory and pricing pressures, leading to the bearish market movement.
• The disclosure of significant ownership stakes by institutional investors like Voya Financial and Vanguard Capital Management might have influenced market sentiment, contributing to the downward trend in TNDM stock.
• Despite TD Cowen raising Tandem Diabetes' price target and maintaining a Buy rating, the overall market reaction to the news about the pay-as-you-go program and Mobi Tubeless product may have been overshadowed by other factors, resulting in the bearish movement observed today.

11.04.2026 - TNDM Stock was down 6.2%

• Tandem Diabetes Care (TNDM) displayed a reduction in losses during Q4 2025, challenging bearish views and suggesting the potential for improved profit margins going forward.
• Mizuho Securities maintained a Hold rating on TNDM while increasing the target price to $24, reflecting their continuous evaluation of the company's financial outlook.
• Despite receiving FDA clearance for its Control-IQ+ technology for pregnancy use, TNDM's stock price has declined year-to-date, prompting discussions about undervaluation and a potential fair value of $30.76.
• Tandem Diabetes Care announced strong financial results for Q1 2026, including record pump shipments and sales, showcasing its dedication to innovation and expansion.

06.04.2026 - TNDM Stock was down 6.0%

• Investor concerns about potential dilution of existing shares following an upsized private placement of convertible senior notes may have influenced the negative market sentiment.
• Despite the FDA clearance for Control-IQ+ technology for pregnant individuals with type 1 diabetes, worries about execution risks related to new distribution models and regulatory pressures could have outweighed the positive news.
• The disclosure of substantial ownership stakes by institutional investors such as Voya Financial and Vanguard Capital Management could have led to increased selling pressure as some investors may view this as a lack of confidence in TNDM's short-term prospects.
• Insights driven by pricing data and AI-generated trading strategies pointing out choppy conditions and diverging sentiment across different time frames might have exacerbated uncertainty and contributed to the stock's bearish movement today.

12.04.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care reported impressive Q1 2026 earnings, beating estimates with a revenue of $247.22 million and an EPS of -$0.30, showing a 5.46% year-over-year increase. This positive financial performance likely fueled investor confidence and contributed to the bullish movement in the stock.
• Despite the record sales and positive operational progress, the stock initially dropped by 14.14% in after-hours trading, possibly due to investor concerns. However, the company's reaffirmation of its full-year guidance and growth expectations from new technologies and business models could have reassured investors, leading to the bullish trend.
• Truist Financial maintaining a Buy rating on Tandem Diabetes Care, albeit with a slightly reduced target price, indicates continued optimism in the company's future prospects. This vote of confidence might have further supported the bullish momentum in the stock.
• Tandem Diabetes Care's strategic initiatives, such as expanding internationally, launching new products like Control-IQ+ for pregnant women, and addressing supply chain challenges, demonstrate a proactive approach to growth. These factors, combined with the positive earnings report, likely contributed to the bullish market movement of the stock.